Latest News | Eris Lifesciences Forms JV with MJ Biopharm to Enter Insulin Segment

New Delhi, Dec 3 (PTI) Drug maker Eris Lifesciences on Friday said it has formed a joint venture with Mumbai-based MJ Biopharm to enter the insulin segment.

Eris MJ Biopharm, the 70:30 joint venture (with Eris holding a 70 per cent stake), would primarily engage in marketing and distribution of human and analogue insulin including Aspart, Glargine and Lispro and GLP-1 agonists and potentially other biopharma products in India.

Also Read | Xiaomi 11T Pro Reportedly Spotted on Bluetooth SIG Certification Site, India Launch Soon.

MJ will be responsible for the development, manufacturing and supply of these products to the JV.

"With the formation of this JV with MJ, we are taking our commitment a step further. Over the next 10-15 years, growth in diabetes care will be driven by DPP4-SGLT2 combinations, Insulin Analogues and GLP1 agonists, given the superior clinical evidence on their ability to provide better glycemic control, cardio-renal protection, and weight management," Eris Lifesciences Chairman and Managing Director Amit Bakshi said in a statement.

Also Read | Oppo Pad Tablet With Snapdragon 870 SoC Tipped To Debut in India Next Year: Report.

With the formation of this JV, the company will add Human Insulin, Analogues and GLP-1 agonists to its portfolio, which along with other devices makes it a full-service player in diabetes care, he added.

"I am excited about this collaboration with Eris and we look forward to expand the breadth and depth of the Insulin market in India," MJ Biopharm Managing Director Amol Shah stated.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)